Related references
Note: Only part of the references are listed.RESEARCHERS FEAR VACCINE HESITANCY IN DEVELOPING NATIONS
Smriti Mallapaty
NATURE (2022)
Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients
A. Jayk Bernal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients
R. L. Gottlieb et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Vaccines to prevent COVID-19: A living systematic review with Trial Sequential Analysis and network meta-analysis of randomized clinical trials
Steven Kwasi Korang et al.
PLOS ONE (2022)
A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus
William A. Fischer et al.
SCIENCE TRANSLATIONAL MEDICINE (2022)
Merck’s COVID pill loses its lustre: what that means for the pandemic
Max Kozlov
NATURE (2021)
REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19
D. M. Weinreich et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab
Anil Gupta et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Interventions for treatment of COVID-19: Second edition of a living systematic review with meta-analyses and trial sequential analyses (The LIVING Project)
Sophie Juul et al.
PLOS ONE (2021)
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
Matthew J. Page et al.
BMJ-BRITISH MEDICAL JOURNAL (2021)
Safety, Virologic Efficacy, and Pharmacokinetics of CT-P59, a Neutralizing Monoclonal Antibody Against SARS-CoV-2 Spike Receptor-Binding Protein: Two Randomized, Placebo-Controlled, Phase I Studies in Healthy Individuals and Patients With Mild SARS-CoV-2 Infection
Jin Yong Kim et al.
CLINICAL THERAPEUTICS (2021)
Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study
Saye H. Khoo et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2021)
Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19
M. Dougan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Clinical Characteristics of Coronavirus Disease 2019 in China
W. Guan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19
B. Cao et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Interventions for treatment of COVID-19: a protocol for a living systematic review with network meta-analysis including individual patient data (The LIVING Project)
Sophie Juul et al.
SYSTEMATIC REVIEWS (2020)
Drug treatments for covid-19: living systematic review and network meta-analysis
Reed A. C. Siemieniuk et al.
BMJ-BRITISH MEDICAL JOURNAL (2020)
A real-time dashboard of clinical trials for COVID-19
Kristian Thorlund et al.
LANCET DIGITAL HEALTH (2020)
RoB 2: a revised tool for assessing risk of bias in randomised trials
Jonathan A. C. Sterne et al.
BMJ-BRITISH MEDICAL JOURNAL (2019)
False-positive findings in Cochrane meta-analyses with and without application of trial sequential analysis: an empirical review
Georgina Imberger et al.
BMJ OPEN (2016)
Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods
Janus Christian Jakobsen et al.
BMC MEDICAL RESEARCH METHODOLOGY (2014)
Bias due to lack of patient blinding in clinical trials. A systematic review of trials randomizing patients to blind and nonblind sub-studies
Asbjorn Hrobjartsson et al.
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY (2014)
Observer bias in randomized clinical trials with measurement scale outcomes: a systematic review of trials with both blinded and nonblinded assessors
Asbjorn Hrobjartsson et al.
CANADIAN MEDICAL ASSOCIATION JOURNAL (2013)
Observer bias in randomised clinical trials with binary outcomes: systematic review of trials with both blinded and non-blinded outcome assessors
Asbjorn Hrobjartsson et al.
BMJ-BRITISH MEDICAL JOURNAL (2012)
Evidence at a glance: error matrix approach for overviewing available evidence
Frederik Keus et al.
BMC MEDICAL RESEARCH METHODOLOGY (2010)
Interpreting meta-analysis according to the adequacy of sample size. An example using isoniazid chemoprophylaxis for tuberculosis in purified protein derivative negative HIV-infected individuals
Mills
Clinical Epidemiology (2010)
Estimating required information size by quantifying diversity in random-effects model meta-analyses
Jorn Wetterslev et al.
BMC MEDICAL RESEARCH METHODOLOGY (2009)
Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses?
Kristian Thorlund et al.
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY (2009)
Apparently conclusive meta-analyses may be inconclusive-Trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses
Jesper Brok et al.
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY (2009)
Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses
Jesper Brok et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2008)
Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis
Jorn Wetterslev et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2008)
Bias in clinical intervention research
LL Gluud
AMERICAN JOURNAL OF EPIDEMIOLOGY (2006)
Being sceptical about meta-analyses: a Bayesian perspective on magnesium trials in myocardial infarction
JPT Higgins et al.
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY (2002)
Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses
LL Kjaergard et al.
ANNALS OF INTERNAL MEDICINE (2001)
Systematic reviews in health care -: Assessing the quality of controlled clinical trials
P Jüni et al.
BMJ-BRITISH MEDICAL JOURNAL (2001)
Share Paper
